Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy

Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy

Immunization of patients with autologous, ex vivo matured dendritic cell (DC) preparations, in order to prime antitumor T-cell responses, is the focus of intense research. Despite progress and approval of clinical approaches, significant enhancement of these personalized immunotherapies is urgently...

Full description

Bibliographic Details
Main Authors: Emily Gwyer Findlay, Andrew J. Currie, Ailiang Zhang, Jana Ovciarikova, Lisa Young, Holly Stevens, Brian J. McHugh, Marta Canel, Mohini Gray, Simon W.F. Milling, John D.M. Campbell, John Savill, Alan Serrels, Donald J. Davidson
Format: Article
Language:English
Published: Taylor & Francis Group 2019-08-01
Series:OncoImmunology
Subjects:
immunotherapy
dendritic cells
cathelicidin
cd103
pd1
cancer
host defense peptide
clec9a
cd86
cd141
cross-presentation
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1608106

Internet

http://dx.doi.org/10.1080/2162402X.2019.1608106

Similar Items